The Infectious Diseases Society of America updated its guidelines for the management of acute or persistent infectious diarrhea.
Refractory Helicobacter pylori infection can be successfully treated with goshuyuto and rabeprazole.
In recent years, a link between childhood Helicobacter pylori and gastric cancer in adulthood has elevated the need to detect and treat H pylori in asymptomatic children.
Bezlotoxumab, given with antibacterials for Clostridium difficile, could be effective as a preventive treatment for C difficile infection.
Implementation of rotavirus vaccination correlated with a reduction in acute gastroenteritis related hospitalization rates among children.
The CDC Health Alert Network has issued an advisory regarding an increase in cases of the intestinal illness cyclosporiasis.
Experts review biotherapeutics for the prevention of C difficile infection, including probiotics, fecal microbiota transplantation, and nontoxigenic C difficile.
The addition of bismuth subcitrate to levofloxacin-based triple therapy is not associated with increased effectiveness in patients with Helicobacter pylori infection.
The rate of multiply recurrent Clostridium difficile (mrCDI) was found to be more than 4 times higher than that of original CDI, with important implications for treatment decisions.
Results of a recent study have shown that infection with Clostridium difficile is increasing in frequency and negatively affects clinical and care outcomes in patients with cancer.
Therapeutic donor microbes can remain for months or years in patients who've undergone fecal microbiota transplantation.
Liver cancer has become the fastest growing cause of cancer deaths in the Unites States.
Experts review novel antibiotic therapies that may limit the impact on the gut microbiome, as well as passive immunization products that may bolster the immune response to C difficile toxins and possibly reduce the frequency of toxigenic strains.
A patient who recently acquired a new tattoo developed Vibrio vulnificus septic shock after swimming in seawater, leading to death.
Recurrent Clostridium difficile infection is associated with a significant economic and mortality burden, but new treatment shows promise.
The FDA granted Breakthrough Therapy designation to Synthetic Biologics' ribaxamase SYN-004 for Clostridium difficile infection prevention.
Findings indicate that dysbiotic features that are uniquely ME/CFS-associated may be masked by disturbances arising from the high prevalence of IBS co-morbidity in ME/CFS.
Community-associated C difficile infection in children was linked to the combination of commonly used antibiotics and exposure to the bacterium in the home and outpatient healthcare settings.
The CDC has issued an alert regarding new recommendations for the treatment of Shigella infection.
Researcher found that while Salmonella infections decreased, reported Yersinia, Cryptosporidium, and Shiga toxin-producing E coli infections increased.
A meta-analysis study shows patients who take gastric acid suppressants have a higher risk for recurrent Clostridium difficile infection.
Drs Kociolek and Shulman, from the division of infectious diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago in Illinois, review all the current vaccine candidates in development for Clostridium difficile infection.
The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.
Investigators proposed an algorithm to facilitate the decision-making process of clinical care for patients with very early hepatocellular carcinoma.
Acute STEMI accounted for 29.3% of renal transplant recipients admissions.
Antibiotic resistance to therapies for Clostridium difficile infection are common, and their patterns should be considered in algorithms designed to select therapies.
No difference in the risk of Clostridium difficile infection (CDI) recurrence observed with vancomycin or metronidazole but 30-day mortality risk was significantly lower among patients with severe CDI treated with vancomycin.
A 28-year-old pregnant woman who presented with recurrent C difficile infection underwent a successful fecal microbiota transplant at 18 weeks of gestation.
Outreach strategies doubled the percentage of patients with cirrhosis who underwent ultrasound screening for HCC.
Trial finds the combination of simeprevir, daclatasvir, and sofosbuvir generally safe and well tolerated in HCV patients with decompensated liver disease.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Pediatric Outpatient Antimicrobial Stewardship: Minimizing Antibiotic Duration
- Better Detection and Treatment Needed for H pylori Infections in Children
- Are Antibiotic Stewardship Programs the Antidote to Antibiotic Overuse?
- FDA Approves New Hepatitis B Vaccine for Adults
- Strategies for Preventing Antibiotic Resistance in Acne
- Dual Regimen Provides Simple and Safe Salvage Therapy in HIV-1
- Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV
- Diclofenac Inferior to Norfloxacin for UTI Symptom Relief
- Legionella Linked to Most Drinking Water-Associated Outbreaks
- Preventing HCV Transmission: Utility of Needle/Syringe Programs